Table 3.
Clinical samples (UTM based) were predetermined positive or negative in routine diagnostics (commercial and inhouse methods) and checked for the Del-69/70 and N501Y spike-gene mutations using commercial VirSNiP assays by TIB MOL (Berlin, Germany). Lineages were assigned based on whole genome sequencing. All samples and mutations were correctly detected by the SCOV2_VAR assay.
| SCOV2_VAR_UCT | |||||
|---|---|---|---|---|---|
| Target-1: N501Y |
Target-2: SC2-S |
Target-3: S-Del |
Target-4: SC2-N |
Total | |
|
SARS-CoV-2 positive Non-B.1.1.7, HV69/70 WT |
0/82 | 82/82 | 0/82 | 82/82 | 82 |
| Non-B.1.1.7, Del-HV69/70 | 0/3 | 0/3 | 3/3 | 3/3 | 3 |
| B.1.1.7 lineage | 50/50 | 0/50 | 50/50 | 50/50 | 50 |
| B.1.351 lineage* | 1/1 | 1/1 | 0/1 | 1/1 | 1 |
| SARS-CoV-2 negative | 0/40 | 0/40 | 0/40 | 0/40 | 40 |
| Total Samples | 176 | ||||